KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Ratio (2016 - 2025)

Historic Equity Ratio for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 0.71.

  • TherapeuticsMD's Equity Ratio rose 359.94% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year increase of 359.94%. This contributed to the annual value of 0.71 for FY2024, which is 425.58% up from last year.
  • Per TherapeuticsMD's latest filing, its Equity Ratio stood at 0.71 for Q3 2025, which was up 359.94% from 0.71 recorded in Q2 2025.
  • TherapeuticsMD's Equity Ratio's 5-year high stood at 0.71 during Q3 2025, with a 5-year trough of 1.05 in Q1 2022.
  • Moreover, its 5-year median value for Equity Ratio was 0.56 (2023), whereas its average is 0.26.
  • Its Equity Ratio has fluctuated over the past 5 years, first crashed by 256113.22% in 2022, then skyrocketed by 42591.66% in 2023.
  • Over the past 5 years, TherapeuticsMD's Equity Ratio (Quarter) stood at 0.55 in 2021, then surged by 170.33% to 0.39 in 2022, then skyrocketed by 74.06% to 0.68 in 2023, then increased by 4.26% to 0.71 in 2024, then rose by 0.66% to 0.71 in 2025.
  • Its Equity Ratio stands at 0.71 for Q3 2025, versus 0.71 for Q2 2025 and 0.7 for Q1 2025.